García-Luna P P, Leal-Cerro A, Pereira J L, Navarro E, Trujillo F, Cortés A, Villamil F, Acosta D, Santos C, Revuelta M
Servicios de Endrocrinología, Hospital Virgen del Rocío, Sevilla.
Med Clin (Barc). 1990 Feb 3;94(4):126-9.
The aim of the present study was to evaluate the effectiveness and tolerance of a new pharmaceutical preparation of long acting bromocryptine (bromocryptine depot of L.A.), characterized by the slow release of bromocryptine during 4 or 6 weeks after a deep intramuscular injection. It was administered to 9 patients with macroprolactinoma, 7 of which had visual abnormalities. The tolerance of the drug was excellent, and only one patient had nausea within the first 24 hours. In all cases, PRL values fell between 40% and 97%. All patients with visual abnormalities, including 2 patients with cranial nerve palsy (IIIth and VIIth pairs) returned to normal or improved. In the CT controls carried out after 4 weeks of therapy a reduction in tumor size was observed in 7 of 9 patients. Two patients were operated through the transesphenoidal route, PRL being demonstrated in the immunohistochemical study of the resected specimen. Subsequently, all patients received oral bromocryptine therapy with perfect tolerance. The results show that parenteral long acting bromocryptine is an effective, well tolerated and convenient way to start the therapy of macroprolactinoma, even when severe visual abnormalities are present.
本研究的目的是评估一种长效溴隐亭新制剂（长效溴隐亭 depot）的有效性和耐受性，其特点是在深部肌内注射后 4 或 6 周内溴隐亭缓慢释放。该制剂应用于 9 例大泌乳素瘤患者，其中 7 例有视觉异常。药物耐受性良好，仅 1 例患者在最初 24 小时内出现恶心。所有病例中，泌乳素（PRL）值下降了 40%至 97%。所有有视觉异常的患者，包括 2 例有颅神经麻痹（第 III 和第 VII 对）的患者，视力恢复正常或有所改善。在治疗 4 周后进行的 CT 检查中，9 例患者中有 7 例肿瘤大小缩小。2 例患者经蝶窦入路手术，在切除标本的免疫组织化学研究中检测到 PRL。随后，所有患者口服溴隐亭治疗，耐受性良好。结果表明，即使存在严重视觉异常，胃肠外长效溴隐亭仍是开始治疗大泌乳素瘤的一种有效、耐受性良好且方便的方法。
